261 related articles for article (PubMed ID: 12068382)
21. Tumor-host immune interactions and dendritic cell dysfunction.
Yang L; Carbone DP
Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
[TBL] [Abstract][Full Text] [Related]
22. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells.
Ohta K; Yamaguchi Y; Shimizu K; Miyahara E; Toge T
Anticancer Res; 2002; 22(5):2597-606. PubMed ID: 12529970
[TBL] [Abstract][Full Text] [Related]
23. Novel exosome-targeted CD4+ T cell vaccine counteracting CD4+25+ regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8+ CTL responses.
Hao S; Liu Y; Yuan J; Zhang X; He T; Wu X; Wei Y; Sun D; Xiang J
J Immunol; 2007 Sep; 179(5):2731-40. PubMed ID: 17709486
[TBL] [Abstract][Full Text] [Related]
24. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
Jinushi M; Hodi FS; Dranoff G
Immunol Rev; 2008 Apr; 222():287-98. PubMed ID: 18364009
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cell gene therapy.
Onaitis M; Kalady MF; Pruitt S; Tyler DS
Surg Oncol Clin N Am; 2002 Jul; 11(3):645-60. PubMed ID: 12487060
[TBL] [Abstract][Full Text] [Related]
26. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
27. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
28. The role of T-cell-mediated mechanisms in virus infections of the nervous system.
Dörries R
Curr Top Microbiol Immunol; 2001; 253():219-45. PubMed ID: 11417137
[TBL] [Abstract][Full Text] [Related]
29. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
30. Immune responses to human tumors: development of tumor vaccines.
Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
[TBL] [Abstract][Full Text] [Related]
31. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
32. Considerations on clinical use of T cell immunotherapy for cancer.
Plautz GE; Cohen PA; Shu S
Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
[TBL] [Abstract][Full Text] [Related]
33. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
34. Vaccination against human cancers (review).
Sinkovics JG; Horvath JC
Int J Oncol; 2000 Jan; 16(1):81-96. PubMed ID: 10601552
[TBL] [Abstract][Full Text] [Related]
35. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
Bodey B; Siegel SE; Kaiser HE
In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
[TBL] [Abstract][Full Text] [Related]
36. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
37. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
38. From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas.
Chaperot L; Jacob MC; Molens JP; Manches O; Bensa JC; Plumas J
Leuk Lymphoma; 2000 Jul; 38(3-4):247-63. PubMed ID: 10830732
[TBL] [Abstract][Full Text] [Related]
39. Enhanced suppression of polyclonal CD8
Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
[TBL] [Abstract][Full Text] [Related]
40. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
